Physician profile
Miranda Brown
NPI 1194477182
$1,185.51
in general payments reported to CMS, 2019-2025
22 companies · $357 in 2025
The $357 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $400 · 2024: $428 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,185.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $208.09 | 2023-2025 | |
| Lilly USA, LLC | $94.11 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $74.42 | 2023-2025 | Wegovy |
| Pfizer INC. | $73.94 | 2023 | |
| Astellas Pharma US INC | $68.69 | 2023-2025 | Veozah |
| Xeris Pharmaceuticals, INC. | $64.54 | 2023-2025 | Gvoke Hypopen, Keveyis |
| Organon LLC | $57.42 | 2023-2025 | Nexplanon |
| Merck Sharp & Dohme LLC | $55.75 | 2023-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $52.44 | 2024-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $48.74 | 2023 | Austedo Xr, Austedo |
| Exact Sciences Corporation | $48.07 | 2023-2025 | Cologuard Collection Kit |
| Philips North America LLC | $45.65 | 2024 | (8874) Incourage |
| Astrazeneca Pharmaceuticals LP | $43.71 | 2024-2025 | Airsupra |
| Abbott Laboratories | $41.78 | 2024-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $35.67 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $35.28 | 2024 | Spravato |
| Dexcom, INC. | $33.22 | 2024-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $31.49 | 2023-2024 | Trelegy Ellipta |
| Neurocrine Biosciences, INC. | $22.36 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $17.81 | 2024 | Rexulti |
| Amgen INC. | $16.82 | 2024 | Evenity, Prolia |
| Lundbeck LLC | $15.51 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miranda Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.